Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. They prioritize patients, drive scientific innovation, and promote health equity while maintaining integrity and sustainability in their operations.

SOCIALS

Updated 4 weeks ago

How woke is Bristol-Myers Squibb?

Introduction

Bristol-Myers Squibb (BMS), a prominent global biopharmaceutical company, has taken notable steps in corporate social responsibility. The company’s approach reflects its active participation in social justice, DEI (Diversity, Equity, and Inclusion) policies, and support for various community-driven causes. 

This review delves into how BMS aligns with progressive values and assesses its branding strategies, training programs, and societal stances.

Financial Contributions to Progressive Causes 

BMS has demonstrated significant involvement in financially supporting progressive initiatives. The company’s health equity grant programs aim to improve outcomes for underserved communities, showcasing its commitment to reducing disparities in healthcare access. 

As noted in BMS’s policy transparency reports, the company contributes to initiatives promoting equality and health-focused causes: “Our transparency reports detail policy and advocacy engagement, including significant contributions to initiatives supporting equality and health-focused causes.”

Prioritization of DEI Policies 

Diversity and inclusion are embedded in BMS’s corporate culture, underscored by comprehensive reports and strategic objectives. According to BMS’s 2021 Diversity and Inclusion report, the company focuses on long-term inclusion goals that encourage equitable opportunities for employees from all backgrounds. 

This is echoed in external assessments by PwC, which highlight BMS’s efforts to foster a workplace that is inclusive of diverse talent. “Our global diversity and inclusion efforts aim to create a culture where everyone feels valued and included, enabling the best contributions from our diverse talent,” reinforces the company’s commitment.

Mandatory Training Sessions 

BMS enforces training programs to address implicit bias and foster an inclusive culture. These programs are part of their broader strategy to instil awareness, foster understanding and address implicit bias among employees, reinforcing the company’s commitment to an inclusive workplace culture.

Support for LGBTQ+ Initiatives 

BMS’s active involvement in LGBTQ+ initiatives is notable. The company has partnered with NJ Pride Chamber of Commerce, emphasizing its commitment to inclusivity. Their Pride Alliance reflects BMS’s dedication to internal support and broader societal advocacy: “Our Pride Alliance and partnerships, like with the NJ Pride Chamber of Commerce, reflect our continuous support for the LGBTQ+ community, both within the company and in broader society.” 

Additionally, programs focusing on addressing LGBTQ+ health disparities highlight BMS’s alignment with social equity in healthcare.

Marketing and Branding 

BMS’s marketing strategy integrates its commitment to social advocacy with a patient-centered approach. Their rebranding, characterized by a bold purple color, symbolizes a modernized identity designed to resonate with patients and foster engagement. “The new identity update, marked by adopting a bold purple color, underscores BMS’s strategic vision of modernized patient engagement and brand recognition,” as noted by industry sources. 

Furthermore, campaigns like “Sotyktu” for psoriasis awareness are designed to reflect patient narratives and align with empathetic storytelling.

Conclusion 

Bristol-Myers Squibb’s robust commitment to social advocacy is evident across its policies and initiatives. From financial support for progressive causes to comprehensive DEI strategies and LGBTQ+ sponsorships, BMS embodies many traits associated with a “woke” brand. While these efforts have earned accolades, they also invite scrutiny from those questioning the balance between advocacy and merit-driven practices.

0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments

Our rating is based

on these article and sources.

Does Bristol-Myers Squibb have woke marketing?

CNBC

Karuna Therapeutics surges 47% after Bristol Myers Squibb...

Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna's stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%.

0
Would love your thoughts, please comment.x
()
x